Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kenneth Pienta Insider Profile
4 Followers
Kenneth Pienta, Director at Curis, holds 2.00K shares in Cue Biopharma (Ticker: CUE), holds 30.00K shares in Curis (Ticker: CRIS). Most recently, Kenneth Pienta Bought ― shares of Cue Biopharma on Jan 19, 2018 for an estimated value of 15.00K.
Profitable Transactions
0 out of 3 Profitable Transactions
Average Return
-55.00%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
The most profitable trade made by Kenneth Pienta
Kenneth Pienta's Trading History
Curis
Nov 08, 2013
Director
Informative Buy
43.60K
$43.20K
Cue Biopharma
Jan 19, 2018
CMO
Informative Buy
15.00K
$27.48K
List of latest transactions for each holding click on a transaction to see Kenneth Pienta's performance on stock
You May Also Like
Kenneth Pienta insider profile FAQ
What is the percentage of profitable transactions made by Kenneth Pienta?
The percentage of profitable transactions made by Kenneth Pienta is 0%.
What is the average return per transaction made by Kenneth Pienta?
The average return per transaction made by Kenneth Pienta is -55.00%.
What stocks does Kenneth Pienta hold?
Kenneth Pienta holds: CRIS, CUE stocks.
What was Kenneth Pienta’s latest transaction?
Kenneth Pienta latest transaction was an Informative Buy of $15.00K.
What was Kenneth Pienta's most profitable transaction?
Kenneth Pienta’s most profitable transaction was an Informative Buy of CRIS stock on November 8, 2013. The return on the trade was -52.70%.
What is Kenneth Pienta's role in Curis?
Kenneth Pienta's role in Curis is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.